Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Vandana Singh

AbbVie Walks Away From Parkinson's Drug Pact With BioArctic

  • AbbVie Inc (NYSE:ABBV) has ended a research partnership with Sweden's BioArctic, backing out further development of an experimental Parkinson's disease drug and other related medicines.
  • A clinicaltrials.gov listing for ABBV-0805 says a Phase I study is "Withdrawn (Strategic considerations)."
  • The partnership between AbbVie and BioArctic, which began in 2016, was focused on antibody drugs targeting alpha-synuclein. This protein can misfold and accumulate abnormally in the brains of patients with Parkinson's and related dementias. 
  • In 2019, a Phase 1 study of the lead asset, ABBV-0805, was initiated. The results from the study, presented at the International Congress of Parkinson's Disease and Movement Disorders in September 2021, support a continuation into Phase 2 with once-monthly dosing.
  • "We are disappointed that AbbVie has taken this decision," CEO Gunilla Osswald said in a prepared statement. "All available data indicates that ABBV-0805 has uniquely high selectivity for the pathological forms of aggregated alpha-synuclein and Phase 1 data supporting progression to Phase 2."
  • AbbVie terminated its Parkinson's disease agreement with Voyager Therapeutics Inc (VYGR) in August 2020, which focused on alpha synuclein-focused vectorized antibodies.
  • Price Action: ABBV shares are up 0.74% at $157.51 during the market session on the last check Wednesday.
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.